Identifying senescence in cancer provides a particular challenge, as reliable markers such as initiation of a DNA damage response (DDR) or positive senescence-associated beta galactosidase (SA-ß-Gal) staining are often already observed in proliferating cancer cells [1, 12]. The gene discussed is GAL; the disease is cancer.